



OncoBioPharm Ltd receives £100,000 grant from Scottish Enterprise.

Edinburgh, Scotland, 1st May 2016.

OncoBioPharm Ltd, a dynamic Edinburgh-based biotechnology company, today announced that it is to receive a grant of £100,000 via SMART: SCOTLAND.

SMART is a Scottish Enterprise initiative which provides grants to carefully selected Small to Medium Enterprises based in Scotland, to help fund research and development projects that have a commercial endpoint.

OncoBioPharm's lead product is Tensinomab[®], a novel antibody which has been shown to block cancer cell growth, invasion and metastasis in a variety of tumour models.

Professor Chris Wood, Chairman of OncoBioPharm, said "The OncoBioPharm team is delighted to have been chosen by Scottish Enterprise to receive this valuable support via the SMART: SCOTLAND scheme".

About Scottish Enterprise

Scottish Enterprise is a non-departmental public body of the Scottish Government committed to encouraging Scotland's economic development through investment, internationalisation, innovation and inclusive growth.

About OncoBioPharm

OncoBioPharm Ltd is a Scottish biotechnology company developing therapeutic antibodies that target novel pathways associated with cancer cell growth and metastasis. These new targets provide OncoBioPharm with the potential to develop new powerful anti-cancer agents, with a focus on extending and improving the lives of people with cancer.